Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...

SAN FRANCISCO -- For the first time today, Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin ...

Among 475 patients randomized in a 1:1:1:1 fashion, those on one of three doses of injectable tirzepatide -- 5 mg, 10 mg, or 15 mg -- in addition to insulin glargine saw a significantly greater mean ...

"Continuing to research our medicines beyond the initial clinical trial program is important for patients and for the ongoing study of diabetes," said Brad Woodward, M.D., senior medical director, ...

In adults, insulin glargine (a long-acting insulin analog) reduces the risk of nocturnal hypoglycemia and improves control of morning blood glucose levels; however, most published studies included ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a new drug application for a biosimilar to insulin glargine injection in vial and prefilled ...

If low glucose events occur, Dexcom Smart Basal lowers the user’s insulin dose recommendation by the amount set by their ...

TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product ...